Maria G. Raso, M.D.
Department of Translational Molecular Pathology, Division of Pathology-Lab Medicine Div
About Dr. Maria G. Raso
Maria Gabriela Raso MD
Assistant Professor
Department of Translational Molecular Pathology
I am an Assistant Professor at the Department of Translational Molecular Pathology University of Texas MD Anderson Cancer Center (MDACC). I am also the Director of the Breast Cancer Research and the ICT TMP Pathology Laboratory and the CCSG Research Histology Core Laboratory. I have extensive experience in anatomic and surgical pathology, one of my major research interests is the elucidation of the molecular abnormalities involved in the pathogenesis and progression of cancer and the characterization of PDX models and their primary tumors. My research interests also include identifying new molecular targets, validating biomarkers for targeted therapy and immunotherapy, and identifying molecular markers (genomic intra-tumor heterogeneity, oncogenes activation, tumor microenvironment) associated with tumor development, progression, and metastasis development using annotated human specimens.
Percent Effort
C Clinical Activities 0
A Administrative Activities (internal service) 20%
R Research Activities 60%
E Education Activities 20%
S Service (extramural – outside of MD Anderson) DESCRIBED BELOW
Activity Summary
CLINICAL ACTIVITIES
None.
ADMINISTRATIVE ACTIVITIES 20%
Leadership:
In September 2018, I assumed the role of Associate Director at the NIH Cancer Center Support Grant (CCSG) Research Histology Core Laboratory (RHCL), where I undertook a multifaceted role with both, operational and administrative responsibilities. This pivotal position not only allowed me to contribute significantly to the core's daily operations but also provided me with invaluable opportunities for leadership development. In recognition of my dedication and proficiency, I was appointed as the RHCL Director in 2020, a testament to my ability to effectively steer the core towards its goals.
In my capacity as Director, I serve as the primary liaison for the core, representing its interests and accomplishments in a variety of internal and external forums, including vital engagements related to CCSG grant renewals and annual reports. My responsibilities encompass the strategic management of the core's budget, ensuring fiscal responsibility and optimal resource allocation. Moreover, I play a pivotal role in the recruitment and supervision of personnel, fostering a dynamic and cohesive team environment conducive to innovation and excellence."
Consultation:
As an expert research pathologist, I serve as a trusted advisor to numerous investigators within the institution, offering invaluable guidance and support as they navigate the intricacies of their projects within the Core. My consultations span a wide spectrum, from assisting with basic sectioning procedures to the implementation of intricate assays, all with a keen focus on ensuring stringent quality parameters..
In this capacity, I provide comprehensive scientific oversight of pathology services, offering insights that optimize experimental design and execution. Particularly adept in advanced techniques such as Immunohistochemistry, CISH, and mIF, I leverage my expertise to not only ensure the accurate interpretation of results but also to elevate the overall standard of research conducted within the institution.
Quality Improvement:
My pivotal role in securing institutional funding for an automated Tissue Microarray (TMA) machine, and a GT450 digital imaging scanner with the objective to incorporating cutting-edge technology, stands as a testament to my commitment to advancing quality improvement initiatives within the institution. This state-of-the-art equipment enhances the efficiency and accuracy of our research endeavors.
Moreover, my dedication to Quality Management (QM) practices has yielded tangible improvements across all facets of RHCL activities. Through the strategic implementation of a comprehensive QM system, I have catalyzed transformative enhancements in the outcomes of various assays, including Immunohistochemistry (IHC), miRNAscope, RNAscope, and Multiplex Immunofluorescence (IF). By providing in-depth scientific oversight and educational resources to our skilled technicians, I've empowered them to execute assays with unparalleled precision and efficacy.
Furthermore, my proactive approach to identifying and addressing deviations through the integration of non-conformance reports into our daily operations has fostered a culture of continuous improvement. This holistic approach has not only optimized the workflows of histology activities but has also elevated the overall quality of our outputs, ensuring that RHCL remains at the forefront of scientific excellence.
RESEARCH ACTIVITIES 60%
As the lead investigator in the Breast Cancer Translational Pathology field, I maintain a balanced portfolio of collaborative endeavors and personal projects. My primary research objective, centered on Invasive Lobular Carcinoma of the Breast (ILC), continues to yield promising results. Our exploration of the intricate interactions within the ILC tumor microenvironment culminated in the submission of two abstract presentations to the 2022 Digital Pathology Conference and the San Antonio Breast Cancer Symposium (SABC) 2022, showcasing our insights into Tumor-Infiltrating Lymphocytes (TILs) using multiplex immunofluorescence (mIF) and the spatial distribution of Cancer-Associated Fibroblasts (CAFs) across different histological variants of ILC. Furthermore, these findings have been disseminated through a senior-authored publication in Cancers journal, marking a significant contribution to the underexplored field of ILC research.
Continuing this trajectory, our efforts have expanded to encompass a broader array of cases, further solidifying the importance of our findings in guiding potential therapeutic interventions. Additionally, our commitment to advancing knowledge in ILC is evident in the publication of a review paper, where I served as the senior author, elucidating the translational aspects of this enigmatic disease.
Beyond ILC, my research endeavors extend to the interrogation of prognostic and predictive biomarkers in breast carcinoma, with a focus on validating and optimizing novel biomarkers that promise to enhance our understanding of molecular pathways underlying this malignancy. Of note, I am actively investigating EMT pathways in Breast Metaplastic Carcinoma histological variants..
Simultaneously, I spearhead various breast-related projects within the ALLIANCES framework, including the Breast Moonshot initiative and clinical trials sponsored by EMD Serono and SANOFI. In this capacity, I oversee multiplex immunofluorescence (mIF) supervision, quality control activities, data analysis, and deliver monthly presentations to ensure the seamless progression of these projects.
My involvement in the Interventional Cancer Therapeutics Department further underscores my commitment to advancing cancer research. As the ICT TMP Lab director, I oversee all laboratory activities and personnel, driving forward multiple mIF and IHC-related projects. Notably, my contributions to Dr. Meric’s group have been pivotal in facilitating CLIA validation of four novel biomarkers, poised to shape future clinical trials.
In the Lung Cancer research field, I collaborated on several fronts, notably leading the GEMINI projects focused on Small Cell Lung Cancer (SCLC) and contributing to NSCLC TMA development. Additionally, my mentorship of a research investigator and investigation into tumor-associated antigens in lung cancer underscores my commitment to advancing knowledge in this field.
As a co-investigator in several awarded grants, including the DOD Dr. Hunt (BM) and Brown University subcontract award (Dr. Mani and Van Hollander), I play a crucial role as the Pathology Core leader, ensuring the seamless integration of pathology expertise across various research endeavors.
In summary, through a combination of personal research initiatives and collaborative efforts across multiple departments, I am dedicated to driving impactful advancements in cancer research, aligning with the institution’s overarching mission to end cancer.
EDUCATION ACTIVITIES 20%
My educational endeavors seamlessly intertwine with my primary responsibilities. Currently, I am actively engaged in mentoring a post-doctoral fellow in my lab, as well as overseeing the development of project designs and data curation for two research investigators.
Within the RHCL (Research Histology and Clinical Laboratory), I provide guidance to both the Research Data Coordinators team and the histotechnical group, ensuring quality standards are met and supporting them in navigating complex assays and histological procedures.
Over the past years, I've spearheaded two iterations of the ITERT course 'Histology for Basic Scientists,' delivered entirely online with exceptional success. Moreover, as the director of the 2023-2024 ITERT session titled 'Fundamental Pathology for Basic Scientists,' I meticulously planned, coordinated, and delivered numerous lectures to facilitate comprehensive learning experiences.
SERVICE
Minorities in Cancer Research (MICR) Member: A membership group within the AACR committed to preventing and curing cancer while meeting the professional needs and advancing the careers of minority scientists. I am a member of this chapter since 2008, This year I have attended the AACR-MICR Jane Cook Wright Lectureship which recognizes an outstanding scientist who has made meritorious contributions to the field of cancer research and the MICR Town Hall
Women in Cancer Research (WICR) Member: attended a series of professional advancement sessions that took during the AACR Annual Meeting 2022.
AACR Cancer Immunology Working Group (CIMM): The mission of the AACR Cancer Immunology Working Group is to provide an ongoing forum for scholarly discussion of the complex relationships between the immune system and tumor cells along the continuum of cancer research.
AACR Tumor Microenviroment Working Group (TME) The mission of the Tumor Microenvironment Working Group (TME) is to provide an opportunity for a diverse group of scientists with a common interest in the tumor microenvironment to guide the AACR in its mission to prevent and cure cancer by activities directed at understanding the impact of the microenvironment on cancer initiation and progression.
MDACC Organization for Women (OFW) Member: OFW is an employee network and is an extension of the Diversity Council and an important part of the Institution’s Diversity Programs.
AACR Grant Award Committee Member 2024-2026 : 2023-2024 AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Grants Scientific Review Committee
Grant Reviewer for M.J. Murdock Charitable Trust
ITERT Summer program 2023: Chair
Journal Peer Reviewer in several scientific journals, as for example: Medicine, Journal of Personalized Medicine, Cancers, Clinical and Translational Medicine among others.
Editorial Board Member of Cancers MDPI and Breast Communications.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Translational Molecular Pathology, Division of Pathology-Lab Medicine Div, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Director, CCSG Research Histology Core laboratory, Department of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
RESEARCH STATEMENT
MARIA GABRIELA RASO MD
The overall goal of my research journey is the dedication to unraveling the complexities of cancer pathogenesis and progression. In addition to my academic role, I serve as the Director of the Breast Cancer Research and the ICT TMP Pathology Laboratory, where I spearhead investigations into the molecular underpinnings of cancer and drive translational discoveries and the director of the CCSG Research Histology Core Laboratory that services all CCSG programs and investigators in our institution.
Background and Accomplishments:
I started my research journey in 2006 as a postdoctoral fellow in Pathology Research under the direct supervision of Dr. Ignacio Wistuba. I continued with my first academic appointments as an instructor focused on thoracic malignancies pathology research. During that time, I had extensively collaborated with UT Southwestern, Baylor College of Medicine, and other institutions[1-6]. These collaborations led to the publication of a landmark paper on Estrogen receptors in Lung carcinomas and its association with EGFR mutation, among others[7] [1-3, 5, 8-17]. After a few years dedicated exclusively to the clinical practice of Anatomic Pathology, I returned to MD Anderson as an Assistant Professor in the Department of Translational Molecular Pathology in 2018.
With expertise in anatomic and surgical pathology, my research endeavors are grounded in a comprehensive understanding of disease mechanisms. My primary focus lies in elucidating the molecular abnormalities that drive cancer initiation, progression, and metastasis[18-23]. Through meticulous inquiry and analysis, I strive to uncover the intricate molecular landscape of tumors, with a particular emphasis on Lung and Breast Carcinoma[24-32].
A cornerstone of my research portfolio involves the characterization of patient-derived xenograft (PDX) and organoid models, alongside their primary tumors[33-37]. These models serve as invaluable tools for studying tumor biology and therapeutic response, offering insights into tumor heterogeneity and drug resistance mechanisms.
Furthermore, I am deeply engaged in the identification of novel molecular targets and the validation of biomarkers for targeted therapy and immunotherapy. By leveraging cutting-edge techniques in genomic analysis and molecular profiling, I endeavor to uncover actionable targets that hold promise for precision medicine approaches in cancer treatment.
Central to my research work is the integration of multidimensional data from annotated human specimens, in vitro assays, and in vivo models. By dissecting the molecular markers associated with tumor development, progression, and metastasis, I aim to decipher the complex interplay between oncogenic drivers, tumor microenvironment, and therapeutic response.
My research interests extend beyond the laboratory, encompassing the broader domains of Tissue Banking, Mouse Models Pathology, PDX models, and Digital Pathology[31, 32, 34, 35, 38-40]. Through collaborative efforts and interdisciplinary approaches, I aspire to advance our understanding of cancer biology and pave the way for innovative therapeutic strategies.
Confident in my skills and driven by a passion for discovery, I am committed to pushing the frontiers of cancer research at MD Anderson Cancer Center. With a trajectory marked by scholarly excellence and a vision for impactful translational research, I am eager to contribute to the institution's mission of Making Cancer History.
Overview of Significance of Proposed Research Plan
I am focused on the translational aspects of Breast and Lung carcinomas. My research interests include identifying new molecular targets, validating biomarkers for targeted therapy and immunotherapy, and identifying molecular markers (genomic intra-tumor heterogeneity, oncogenes activation, tumor microenvironment) associated with tumor development, progression, and metastasis development using annotated human specimens.
My research program is investigating the following Projects:
Project 1. Invasive Lobular Carcinoma of the Breast (ILC) Tumor Microenvironment
As lead investigator in the Breast Cancer Translational Pathology field, I am achieving a healthy balance between collaborative and personal projects. My personal research goal focused on Invasive Lobular Carcinoma of the Breast (ILC), is progressing nicely. We explored the complex interactions in the ILC tumor microenvironment, our findings were submitted in two abstract presentations to the 2022 Digital Pathology Conference and the San Antonio Breast Cancer SABC 2002, showcasing the TILS mIF profile and the spatial CAFs distribution among ILC histological variants. As an additional outcome, I have published these results as the senior author in Cancers[41]. This project continued by increasing the number of cases and adding macrophages subpopulation densities. These are essential findings, as ILC is poorly investigated and might direct therapeutically targeted therapies.
Project 2. Metaplastic Breast Carcinoma Histopathology Variants Translational insights
Interrogation of prognostic and predictive oncology-related biomarkers in Metaplastic breast carcinoma. I am exploring, validating, and optimizing EMT unexplored biomarkers that will add to the understanding of molecular pathways in this particular entity. Additionally, I have published an extensive review of the translational aspects of these tumors as the senior author in Cancers [41].
Project 3. Exploration and Validation of Biomarkers and PDX models
Part of my research activities are embedded in the Interventional Cancer Therapeutics Department. I am the ICT TMP Lab director and as such, I oversee all lab activities, and personnel as well as different mIF and IHC-related projects. I am participating in several projects, some of them sponsored by pharmaceutical companies. I have been instrumental in the CLIA validation of four novel biomarkers that will be utilized in a clinical trial.
Project 4.Prevalence of different biomarkers associated with newly developed targeted treatments, exploring multiple tissue types and its diagnosis
Focused on targeted therapies associated with ADCs, bi specific antibodies ,cart-t cells, etc, I am exploring biomarkers expression in several tissue types including lung, breast. TNBC, Cholangiocarcinoma, renal cell carcinoma, hepatocarcinoma, glioblastoma, upper gastrointestinal carcinoma, among others.
Project 5: Advancing Lung Carcinoma Research.
In the field of lung cancer research, I collaborate on several fronts, notably leading the GEMINI projects focused on Small Cell Lung Cancer (SCLC) and contributing to a Non-Small Cell Carcinoma Tissue Microarray (NSCLC TMA) development. Currently, I am collaborating with the Lung Cancer Mutation Consortium (LCMC)-4 , leading the Quality Control activities for the assessment of Major Pathological Response (MPR) in patients with stages I-III NSCLC with ALK, ROS1, NTRK, or BRAF mutations. I lead of the TMP tumor-associated antigen exploration in lung cancer project.
Long-term vision/plan
By progressing in my research focus and collaborating with different departments within MDACC, I will drive a significant impact in the cancer research field as well as the Institution’s mission to end cancer. Over the next 5 years, my goal is to continue supporting tissue-based translational projects focusing on the development of targeted therapies and artificial intelligence tools available in the pathology field.
Education & Training
Degree-Granting Education
| 1989 | University Of Buenos Aires, Buenos Aires, AR, Medicine, MD |
| 1981 | National College Perito Moreno, Comodoro Rivadavia, AR, Business, BS in Commerce |
Postgraduate Training
| 2009-2009 | Engineered Mouse Pathology Course Certificate, Pathology Research, UC Davis |
| 2006-2007 | Postdoctoral Research Fellowship, Pathology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2005-2005 | Professional Medical Observer, Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2002-2002 | Diploma Degree, Perinatal Pathology, National Institute of Perinatal Pathology, Mexico City |
| 1989-1992 | Clinical Residency, Anatomic Pathology, Ramos Mejia Hospital, Buenos Aires |
Board Certifications
| 2004 | Mexican Pathologists Association |
| 1992 | Argentinian Pathology Society |
Experience & Service
Academic Appointments
Instructor, Department of Pathology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2010
Administrative Appointments/Responsibilities
Director CCSG Research Histology Core Laboratory, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - Present
Associate Director, CCSG Research Histology Core laboratory, Department of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, 2018 - Present
Other Appointments/Responsibilities
Surgical Oncology Complex Cut Up PA, Private Laboratory, Melbourne, 2017 - 2018
Senior Registrar, Private Laboratory, Perth, 2016 - 2017
Staff Pathologist, Private Laboratory, Dubai, 2011 - 2014
Instructor, Pathology Research, MDACC, Houston, TX, 2007 - 2010
Postdoctoral Research Fellow, Pathology Research, MDACC, Houston, Tx, 2006 - 2007
Professional Medical Observer, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005
Chief Pathologist, Azteca Laboratories, Estado de Mexico, 2004 - 2005
Diplomature in Perinatal Pathology, National Institute of Perinatology, Mexico City, 2002
Medical Pathologist, Private Practice, México City, 2002 - 2004
Associate and consulting physician, LAP SRL, Anatomic Pathology Private laboratory, Trelew, Chubut, Argentina, 1996 - 2004
Chief Pathologist, Private Anatomopathological Laboratory LAP, Trelew, 1996 - 2002
Chief Pathologist, Trelew Municipal Hospital, Chubut, 1992 - 1993
Executive medical translator, Latin American society of Scientific Information SIIC, Buenos Aires Argentina, 1991 - 1993
Institutional Committee Activities
Member, GU Medical Oncology Department Chair Search Committee, 2024 - Present
Judge, Academic Review Committee Division Education and Training, 2023 - Present
Honors & Awards
| 2008 | Travel Award, International Association for the study of Lung Cancer |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Varadarajan K, Cruz Pico CX, Evans KW, Raso MG, Rizvi YQ, Zheng X, Chachad D, DiPeri TP, Wang B, Scott SM, Zhao M, Akcakanat A, Wengner AM, Yap TA, Meric-Bernstam F. Efficacy of ATR kinase inhibitor elimusertib monotherapy or combination in tumors with DNA damage response pathway and other genomic alterations. Mol Cancer Ther, 2025. e-Pub 2025. PMID: 40300249.
- Zheng, L, Tabet, GC, Guo, CC, Rizvi, YQ, Raso, G, Liu, J, Ding, Q, Baraban, EG, Zhao, J. Clinicopathological study of 34 cases of clear cell adenocarcinoma of the urinary tract and diagnostic value of SOX 17 in its differential diagnosis. Human Pathology 157, 2025. e-Pub 2025. PMID: 40189026.
- Zheng L, Tabet G, Guo CC, Rizvi YO, Raso MG, Liu J, Ding Q, Baraban E, Zhao J. Clinicopathological study of 34 cases of clear cell adenocarcinoma of the urinary tract and diagnostic value of SOX 17 in its differential diagnosis. Hum Pathol 157:105767, 2025. e-Pub 2025. PMID: 40189026.
- Visal TH, Bayraktar R, den Hollander P, Attathikhun MA, Zhou T, Wang J, Shen L, Minciuna CE, Chen M, Barrientos-Toro E, Batra H, Raso MG, Yang F, Parra ER, Sahin AA, Calin GA, Mani SA. Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer. Cancer Res 85(5):OF1-OF18, 2025. e-Pub 2025. PMID: 39853244.
- Lermi NO, Ayala MM, Ruiz SH, Lu W, Khan K, Serrano A, Lubo I, Hamana L, Tomczak K, Barnes S, Dou J, Liang Q, Raso MG, Tang X, Jiang M, Sanchez-Espiridion B, Weissferdt A, Heymach J, Zhang J, Sepesi B, Cascone T, Tsao A, Altan M, Mehran R, Gibbons D, Wistuba I, Haymaker C, Chen K, Solis Soto LM. Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples. Res Sq, 2025. e-Pub 2025. PMID: 39877088.
- Ahmed J, Stephen B, Khawaja MR, Yang Y, Salih I, Barrientos-Toro E, Raso MG, Karp DD, Piha-Paul SA, Sood AK, Ng CS, Johnson A, Soliman PT, Meric-Bernstam F, Lu KH, Naing A. A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. Gynecol Oncol 193:73-80, 2025. e-Pub 2025. PMID: 39787747.
- Lyu MA, Tang X, Raso MG, Huang M, Zeng K, Sadeghi T, Flowers CR, Parmar S. Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE. Front Immunol 16:1449693, 2025. e-Pub 2025. PMID: 39975551.
- Ozirmak Lermi N, Molina Ayala M, Hernandez S, Lu W, Khan K, Serrano A, Lubo I, Hamana L, Tomczak K, Barnes S, Dou J, Liang Q, Team R, Raso MG, Tang X, Jiang M, Sanchez-Espiridion B, Weissferdt A, Heymach J, Zhang J, Sepesi B, Cascone T, Tsao A, Altan M, Mehran R, Gibbons D, Wistuba I, Haymaker C, Chen K, Solis Soto LM. Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples. bioRxiv, 2024. e-Pub 2024. PMID: 39763763.
- Meric-Bernstam F, Yuca E, Evans KW, Zhao M, Maejima T, Karibe T, Raso MG, Tang X, Zheng X, Rizvi YQ, Akcakanat A, Scott SS, Wang B, Byers LA, Tripathy D, Okajima D, Damodaran S. Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate Datopotamab deruxtecan in patient-derived breast cancer xenograft models. Clin Cancer Res 31(3):573-587, 2024. e-Pub 2024. PMID: 39585341.
- DiPeri TP, Evans KW, Scott S, Zheng X, Varadarajan K, Kwong LN, Kahle M, Tran Cao HS, Tzeng CW, Vu T, Kim S, Su F, Raso MG, Rizvi Y, Zhao M, Wang H, Lee SS, Yap TA, Rodon J, Javle M, Meric-Bernstam F. Utilizing Patient-derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. Clin Cancer Res 31(2):387-402, 2024. e-Pub 2024. PMID: 39513959.
- Shaitelman SF, Le-Petross H, Raso MG, Swanson DM, Schalck AP, Contreras A, Yang F, Muruganandham M, Zhao GZ, Sawakuchi GO, Kim LH, Batra H, Smith BD, Stauder MC, Woodward WA, Reddy JP, Litton JK, Thompson A, Bedrosian I, Mitten EA. PRECISE: Preoperative Radiotherapy to Elicit Critical Immune Stimulating Effects - A Phase II Clinical Trial. Int J Radiat Oncol Biol Phys 121(1):90-96, 2024. e-Pub 2024. PMID: 39147206.
- Batra H, Bose PSC, Ding Y, Dai A, Chen H, Albarracin CT, Sun H, Sahin AA, Yang F, Wistuba II, Raso MG. MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers. Histopathology 85(3):503-509, 2024. e-Pub 2024. PMID: 38973399.
- White BS, Woo XY, Koc S, Sheridan T, Neuhauser SB, Wang S, Evrard YA, Chen L, Foroughi Pour A, Landua JD, Mashl RJ, Davies SR, Fang B, Raso MG, Evans KW, Bailey MH, Chen Y, Xiao M, Rubinstein JC, Sanderson BJ, Lloyd MW, Domanskyi S, Dobrolecki LE, Fujita M, Fujimoto J, Xiao G, Fields RC, Mudd JL, Xu X, Hollingshead MG, Jiwani S, Acevedo S, Davis-Dusenbery BN, Robinson PN, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Carvajal-Carmona LG, Welm AL, Welm BE, Govindan R, Li S, Davies MA, Roth JA, Meric-Bernstam F, Xie Y, Herlyn M, Ding L, Lewis MT, Bult CJ, Dean DA 2nd, Chuang JH. A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis. Cancer Res 84(13):2060-2072, 2024. e-Pub 2024. PMID: 39082680.
- Acharya S, Basar R, Daher M, Rafei H, Li P, Uprety N, Ensley E, Shanley M, Kumar B, Banerjee PP, Melo Garcia L, Lin P, Mohanty V, Kim KH, Jiang X, Pan Y, Li Y, Liu B, Nunez Cortes AK, Zhang C, Fathi M, Rezvan A, Montalvo MJ, Cha SL, Reyes-Silva F, Shrestha R, Guo X, Kundu K, Biederstadt A, Muniz-Feliciano L, Deyter GM, Kaplan M, Jiang XR, Liu E, Jain A, Roszik J, Fowlkes NW, Solis Soto LM, Raso MG, Khoury JD, Lin P, Vega F, Varadarajan N, Chen K, Marin D, Shpall EJ, Rezvani K. CD28 costimulation augments CAR signaling in NK cells via the LCK/CD3Z/ZAP70 signaling axis. Cancer Discov 14(10):1879-1900, 2024. e-Pub 2024. PMID: 38900051.
- Treekitkarnmongkol W, Shah V, Kai K, Katayama H, Wong J, Ladha FA, Nguyen T, Menegaz B, Lu W, Yang F, Mino B, Tang X, Gagea M, Batra H, Raso MG, Wistuba II, Krishnamurthy S, Pinder SE, Sawyer EJ, Thompson AM, Sen S. Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer. Br J Cancer 131(1):171-183, 2024. e-Pub 2024. PMID: 38760444.
- Raso MG, Barrientos Toro E, Evans K, Rizvi Y, Lazcano R, Akcakanat A, Sini P, Trapani F, Madlener EJ, Waldmeier L, Lazar A, Meric-Bernstam F. Heterogeneous Profile of ROR1 Protein Expression across Tumor Types. Cancers (Basel) 16(10), 2024. e-Pub 2024. PMID: 38791952.
- Patel B, Zhou Y, Babcock RL, Ma F, Zal MA, Kumar D, Medik YB, Kahn LM, Pineda JE, Park EM, Schneider SM, Tang X, Raso MG, Jeter CR, Zal T, Clise-Dwyer K, Keyomarsi K, Giancotti FG, Colla S, Watowich SS. STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response. Leukemia 38(5):1143-1155, 2024. e-Pub 2024. PMID: 38467768.
- Petralia F, Ma W, Yaron TM, Caruso FP, Tignor N, Wang JM, Charytonowicz D, Johnson JL, Huntsman EM, Marino GB, Calinawan A, Evangelista JE, Selvan ME, Chowdhury S, Rykunov D, Krek A, Song X, Turhan B, Christianson KE, Lewis DA, Deng EZ, Clarke DJ, Whiteaker JR, Kennedy JJ, Zhao L, Segura RL, Batra H, Raso MG, Parra ER, Soundararajan R, Tang X, Li Y, Yi X, Satpathy S, Wang Y, Wiznerowicz M, González-Robles TJ, Iavarone A, Gosline SJ, Reva B, Robles AI, Nesvizhskii AI, Mani DR, Gillette MA, Klein RJ, Cieslik M, Zhang B, Paulovich AG, Sebra R, Gümüş ZH, Hostetter G, Fenyö D, Omenn GS, Cantley LC, Ma'ayan A, Lazar AJ, Ceccarelli M, Wang P. Pan-cancer proteogenomics characterization of tumor immunity. Cell 187(5):1255-1277.e27, 2024. e-Pub 2024. PMID: 38359819.
- DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, logo O, Pohlmann PR, Jensen V, Javle M, logo O, Rodon J, Meric-Bernstam F. Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov 14(5):828-845, 2024. e-Pub 2024. PMID: 38358339.
- Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, De Sousa LG, Lewis WE, Kondo K, Hu X, Heymach JV. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer cell 42(2):225-237.e5, 2024. e-Pub 2024. PMID: 38278149.
- Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets. JTO Clin Res Rep 5(2):100623, 2024. e-Pub 2024. PMID: 38357092.
- Zhao M, Wang T, Gleber-Netto FO, Chen Z, McGrail DJ, Gomez JA, Ju W, Gadhikar MA, Ma W, Shen L, Wang Q, Tang X, Pathak S, Raso MG, Burks JK, Lin SY, Wang J, Multani AS, Pickering CR, Chen J, Myers JN, Zhou G. Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. Nat Commun 15(1):180, 2024. e-Pub 2024. PMID: 38167338.
- Kuburich, NA, Den Hollander, P, Castaneda, M, Pietilae, MP, Tang, X, Batra, H, Martínez-Peña, F, Visal, TH, Zhou, T, Demestichas, BR, Dontula, RV, Liu, JY, Maddela, JJ, Padmanabhan, RS, Phi, LH, Rosolen, MJ, Sabapathy, T, Kumar, D, Giancotti, FG, Lairson, LL, Raso, G, Soundararajan, R, Mani, S. Stabilizing vimentin phosphorylation inhibits stem-like cell properties and metastasis of hybrid epithelial/mesenchymal carcinomas. Cell Reports 42(12), 2023. e-Pub 2023. PMID: 37979166.
- Batra Harsh, Pandurengan R, Ibarguen H, Rabassedas NB, Sahin A, Wistuba I, Parra ER, Raso MG. Exploration of cancer associated fibroblasts phenotypes in the tumor microenvironment of classical and pleomorphic Invasive Lobular Carcinoma. Front Oncol, 2023. e-Pub 2023. PMID: 38192631.
- Zhao, M, DiPeri, TP, Raso, G, Zheng, X, Rizvi, YQ, Evans, KW, Yang, F, Akcakanat, A, Roberto Estecio, M, Tripathy, D, Ileana Dumbrava, EE, Damodaran, S, Meric-Bernstam, F. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. npj Breast Cancer 9(1), 2023. e-Pub 2023. PMID: 37567892.
- DiPeri, TP, Evans, KW, Raso, G, Zhao, M, Rizvi, YQ, Zheng, X, Wang, B, Kirby, B, Kong, K, Kahle, M, Yap, TA, Ileana Dumbrava, EE, Ajani, JA, Fu, S, Keyomarsi, K, Meric-Bernstam, F. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clinical Cancer Research 29(21):OF1-OF14, 2023. e-Pub 2023. PMID: 37279095.
- Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, Gorur A, Kirby B, Cimo AM, Kennon A, Ding Q, Urschel G, Yuan Y, Feng G, Rizvi Y, Hussain A, Zhu C, Kim P, Abbadessa G, Subbiah V, Yap TA, Rodon J, Piha-Paul SA, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol 34(11):1035-1046, 2023. e-Pub 2023. PMID: 37619847.
- Patel B, Zhou Y, Babcock RL, Ma F, Zal MA, Kumar D, Medik YB, Kahn LM, Pineda JE, Park EM, Tang X, Raso MG, Zal T, Clise-Dwyer K, Giancotti FG, Colla S, Watowich SS. STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity. bioRxiv, 2023. e-Pub 2023. PMID: 36798265.
- Zhou Y, Medik YB, Patel B, Zamler DB, Chen S, Chapman T, Schneider S, Park EM, Babcock RL, Chrisikos TT, Kahn LM, Dyevoich AM, Pineda JE, Wong MC, Mishra AK, Cass SH, Cogdill AP, Johnson DH, Johnson SB, Wani K, Ledesma DA, Hudgens CW, Wang J, Wadud Khan MA, Peterson CB, Joon AY, Peng W, Li HS, Arora R, Tang X, Raso MG, Zhang X, Foo WC, Tetzlaff MT, Diehl GE, Clise-Dwyer K, Whitley EM, Gubin MM, Allison JP, Hwu P, Ajami NJ, Diab A, Wargo JA, Watowich SS. Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. J Exp Med 220(2), 2023. e-Pub 2023. PMID: 36367776.
- Lyu, M, Tang, X, Khoury, J, Raso, G, Huang, M, Zeng, K, Nishimoto, M, Ma, H, Sadeghi, T, Flowers, CR, Parmar, S. Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus. Frontiers in immunology 14, 2023. e-Pub 2023. PMID: 37736101.
- Batra, H, Ding, Q, Pandurengan, RK, Ibarguen, H, Rabassedas, NB, Sahin, AA, Wistuba, II, Parra Cuentas, ER, Raso, G. Exploration of cancer associated fibroblasts phenotypes in the tumor microenvironment of classical and pleomorphic Invasive Lobular Carcinoma. Frontiers in Oncology 13, 2023. e-Pub 2023. PMID: 38192631.
- Le UQ, Chen N, Balasenthil S, Lurie E, Yang F, Liu S, Rubin L, Solis Soto LM, Raso MG, Batra H, Sahin AA, Wistuba II, Killary AM. Tumor suppressor DEAR1 regulates mammary epithelial cell fate and predicts early onset and metastasis in triple negative breast cancer. Sci Rep 12(1):19504, 2022. e-Pub 2022. PMID: 36376460.
- Bajaj R, Rodriguez BL, Russell WK, Warner AN, Diao L, Wang J, Raso MG, Lu W, Khan K, Solis LS, Batra H, Tang X, Fradette JF, Kundu ST, Gibbons DL. Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasis. Cell Rep 40(13):111429, 2022. e-Pub 2022. PMID: 36170810.
- Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Author Correction: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nat Commun 13(1):4640, 2022. e-Pub 2022. PMID: 35941179.
- Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nat Commun 13(1):4327, 2022. e-Pub 2022. PMID: 35882862.
- Hassane M, Rahal Z, Karaoghlanian N, Zhang J, Sinjab A, Wong JW, Lu W, Scheet P, Lee JJ, Raso MG, Solis LM, Fujimoto J, Chami H, Shihadeh AL, Kadara H. Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the Lung. Cancer Prev Res (Phila) 15(7):423-434, 2022. e-Pub 2022. PMID: 35468191.
- Sun X, Zhai J, Sun B, Parra ER, Jiang M, Ma W, Wang J, Kang AM, Kannan K, Pandurengan R, Zhang S, Solis LM, Haymaker CL, Raso MG, Mendoza Perez J, Sahin AA, Wistuba II, Yam C, Litton JK, Yang F. Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Mod Pathol 35(5):601-608, 2022. e-Pub 2022. PMID: 34839351.
- Labanca E, Bizzotto J, Sanchis P, Anselmino N, Yang J, Shepherd PDA, Paez A, Antico-Arciuch V, Lage-Vickers S, Hoang AG, Tang X, Raso MG, Titus M, Efstathiou E, Cotignola J, Araujo J, Logothetis C, Vazquez E, Navone N, Gueron G. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene 40(44):6284-6298, 2021. e-Pub 2021. PMID: 34584218.
- Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. Cancer Discov 11(10):2506-2523, 2021. e-Pub 2021. PMID: 33972311.
- Padhye A, Konen JM, Rodriguez BL, Fradette JJ, Ochieng JK, Diao L, Wang J, Lu W, Solis LS, Batra H, Raso MG, Peoples MD, Minelli R, Carugo A, Bristow CA, Gibbons DL. Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer. JCI Insight 6(17), 2021. e-Pub 2021. PMID: 34309585.
- Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, Dou Y, Reva B, Kane MH, Avanessian SC, Vasaikar SV, Krek A, Lei JT, Jaehnig EJ, Omelchenko T, Geffen Y, Bergstrom EJ, Stathias V, Christianson KE, Heiman DI, Cieslik MP, Cao S, Song X, Ji J, Liu W, Li K, Wen B, Li Y, Gümüs ZH, Selvan ME, Soundararajan R, Visal TH, Raso MG, Parra ER, Ö B, Vats P, Anand S, Schraink T, Cornwell M, Rodrigues FM, Zhu H, Mo CK, Zhang Y, da Veiga Leprevost F, Huang C, Chinnaiyan AM, Wyczalkowski MA, Omenn GS, Newton CJ, Schurer S, Ruggles KV, Fenyö D, Jewell SD, Thiagarajan M, Mesri M, Rodriguez H, Mani SA, Udeshi ND, Getz G, Suh J, Li QK, Hostetter G, Paik PK, Dhanasekaran SM, Govindan R, Ding L, Robles AI, Clauser KR, Nesvizhskii AI, Wang P, Carr SA, Zhang B, Mani DR, Gillette MA, Analysis Consortium CPT. A proteogenomic portrait of lung squamous cell carcinoma. Cell 184(16):4348-4371.e40, 2021. e-Pub 2021. PMID: 34358469.
- Bota-Rabassedas N, Banerjee P, Niu Y, Cao W, Luo J, Xi Y, Tan X, Sheng K, Ahn YH, Lee S, Parra ER, Rodriguez-Canales J, Albritton J, Weiger M, Liu X, Guo HF, Yu J, Rodriguez BL, Firestone JJA, Mino B, Creighton CJ, Solis LM, Villalobos P, Raso MG, Sazer DW, Gibbons DL, Russell WK, Longmore GD, Wistuba II, Wang J, Chapman HA, Miller JS, Zong C, Kurie JM. Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. Cell Rep 35(3):109009, 2021. e-Pub 2021. PMID: 33882319.
- Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34(4):710-719, 2021. e-Pub 2021. PMID: 33011748.
- Treekitkarnmongkol W, Hassane M, Sinjab A, Chang K, Hara K, Rahal Z, Zhang J, Lu W, Sivakumar S, McDowell TL, Kantrowitz J, Zhou J, Lang W, Xu L, Ochieng JK, Nunomura-Nakamura S, Deng S, Behrens C, Raso MG, Fukuoka J, Reuben A, Ostrin EJ, Parra E, Solis LM, Spira AE, McAllister F, Cascone T, Wistuba II, Moghaddam SJ, Scheet PA, Fujimoto J, Kadara H. Augmented Lipocalin-2 is Associated with COPD and Counteracts Lung Adenocarcinoma Development. Am J Respir Crit Care Med 203(1):90-101, 2021. e-Pub 2021. PMID: 32730093.
- Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, Wei Y, Chapman HA, Yamauchi M, Behrens C, Raso G, Soto LMS, Cuentes ERP, Wistuba II, Kurie JM, Gibbons DL. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun 11(1):4520, 2020. e-Pub 2020. PMID: 32908154.
- Tan X, Banerjee P, Pham EA, Rutaganira FUN, Basu K, Bota-Rabassedas N, Guo HF, Grzeskowiak CL, Liu X, Yu J, Shi L, Peng DH, Rodriguez BL, Zhang J, Zheng V, Duose DY, Solis LM, Mino B, Raso MG, Behrens C, Wistuba II, Scott KL, Smith M, Nguyen K, Lam G, Choong I, Mazumdar A, Hill JL, Gibbons DL, Brown PH, Russell WK, Shokat K, Creighton CJ, Glenn JS, Kurie JM. PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma. Sci Transl Med 12(527), 2020. e-Pub 2020. PMID: 31969487.
- Suraokar, M, Nunez, MI, Diao, L, Chow, CW, Kim, D, Behrens, MC, Lin, Y, Lee, S, Raso, G, Moran, C, Rice, DC, Mehran, RJ, Lee, JJ, Pass, HI, Wang, J, Momin, AA, James, BP, Corvalán R, A, Coombes, KR, Tsao, A, Wistuba, II. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway andmicrotubule network with therapeutic implications. Annals of Oncology 25(6):1184-1192, 2014. e-Pub 2014. PMID: 24669013.
- Wistuba II, Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Riley R, Hughes E, Reid J, Sangale Z, Swisher SG, Kalhor N, Moran CA, Gutin A, Lanchbury JS, Barberis M, Kim ES. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res 19(22):6261-71, 2013. e-Pub 2013. PMID: 24048333.
- Guo C, Shao R, Correa AM, Behrens C, Johnson FM, Raso MG, Prudkin L, Solis LM, Nunez MI, Fang B, Roth JA, Wistuba II, Swisher SG, Lin T, Pataer A. Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC. J Thorac Oncol 8(3):301-8, 2013. e-Pub 2013. PMID: 23370317.
- Jeong Y, Xie Y, Lee W, Bookout AL, Girard L, Raso G, Behrens C, Wistuba II, Gadzar AF, Minna JD, Mangelsdorf DJ. Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. Mol Endocrinol 26(8):1443-54, 2012. e-Pub 2012. PMID: 22700587.
- Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, Galindo H, Tang X, Lee JJ, Kalhor N, Wistuba II, Moran CA. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer 118(11):2889-99, 2012. e-Pub 2012. PMID: 22020674.
- Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG, Research Group UOTMDALCC. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 7(5):825-32, 2012. e-Pub 2012. PMID: 22481232.
- Moussalli MJ, Wu Y, Zuo X, Yang XL, Wistuba II, Raso MG, Morris JS, Bowser JL, Minna JD, Lotan R, Shureiqi I. Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion. Cancer Prev Res (Phila) 4(12):1961-72, 2011. e-Pub 2011. PMID: 21881028.
- Xie Y, Xiao G, Coombes KR, Behrens C, Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, Moran C, Danenberg K, Minna JD, Wistuba II. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res 17(17):5705-14, 2011. e-Pub 2011. PMID: 21742808.
- Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res 71(16):5512-21, 2011. e-Pub 2011. PMID: 21724587.
- Tsuta K, Kalhor N, Raso MG, Wistuba II, Moran CA. Oncocytic neuroendocrine tumors of the lung: histopathologic spectrum and immunohistochemical analysis of 15 cases. Hum Pathol 42(4):578-85, 2011. e-Pub 2011. PMID: 21329962.
- Tsuta K, Raso MG, Kalhor N, Liu DD, Wistuba II, Moran CA. Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer 71(1):34-41, 2011. e-Pub 2011. PMID: 20462655.
- Tsuta K, Raso MG, Kalhor N, Liu DC, Wistuba II, Moran CA. Sox10-positive sustentacular cells in neuroendocrine carcinoma of the lung. Histopathology 58(2):276-85, 2011. e-Pub 2011. PMID: 21323953.
- He Y, Correa AM, Raso MG, Hofstetter WL, Fang B, Behrens C, Roth JA, Zhou Y, Yu L, Wistuba II, Swisher SG, Pataer A. The role of PKR/eIF2α signaling pathway in prognosis of non-small cell lung cancer. PLoS One 6(11):e24855, 2011. e-Pub 2011. PMID: 22102852.
- Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, Honorio S, Xie Y, Scaglioni PP, DiMaio JM, Gazdar AF, Shay JW, Wistuba II, Minna JD. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 70(23):9937-48, 2010. e-Pub 2010. PMID: 21118965.
- Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 5(12):1894-904, 2010. e-Pub 2010. PMID: 21124077.
- Pataer A, Raso MG, Correa AM, Behrens C, Tsuta K, Solis L, Fang B, Roth JA, Wistuba II, Swisher SG. Prognostic significance of RNA-dependent protein kinase on non-small cell lung cancer patients. Clin Cancer Res 16(22):5522-8, 2010. e-Pub 2010. PMID: 20930042.
- Berlin JM, Leonard AD, Pham TT, Sano D, Marcano DC, Yan S, Fiorentino S, Milas ZL, Kosynkin DV, Price BK, Lucente-Schultz RM, Wen X, Raso MG, Craig SL, Tran HT, Myers JN, Tour JM. Effective drug delivery, in vitro and in vivo, by carbon-based nanovectors noncovalently loaded with unmodified Paclitaxel. ACS Nano 4(8):4621-36, 2010. e-Pub 2010. PMID: 20681596.
- Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach J, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD. Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res 70(16):6477-85, 2010. e-Pub 2010. PMID: 20663904.
- Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9(6):1755-63, 2010. e-Pub 2010. PMID: 20530716.
- Jin N, Cho SN, Raso MG, Wistuba I, Smith Y, Yang Y, Kurie JM, Yen R, Evans CM, Ludwig T, Jeong JW, DeMayo FJ. Mig-6 is required for appropriate lung development and to ensure normal adult lung homeostasis. Development 136(19):3347-56, 2009. e-Pub 2009. PMID: 19710174.
- Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II. Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR Mutation. Clin Cancer Res 15(17):5359-68, 2009. e-Pub 2009. PMID: 19706809.
- Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG, Solca F, Wistuba II, Wong KK. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A 106(2):474-9, 2009. e-Pub 2009. PMID: 19122144.
- Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One 4(4):e5401, 2009. e-Pub 2009. PMID: 19404390.
- McDonald JM, Pelloski CE, Ledoux A, Sun M, Raso G, Komaki R, Wistuba II, Bekele BN, Aldape K. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung,. Clin Cancer Res 14(23):7832-7, 2008. e-Pub 2008. PMID: 19047111.
- Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, Wistuba II, Lotan R. Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer. Clin Cancer Res 14(14):6014-6022, 2008. e-Pub 2008. PMID: 18829480.
- Zhang J, Iwanaga K, Choi KC, Wislez M, Raso MG, Wei W, Wistuba II, Kurie JM. Intratumoral Epiregulin Is a Marker of Advanced Disease in Non-Small Cell Lung Cancer Patients and Confers Invasive Properties on EGFR-Mutant Cells. Cancer Prev Res (Phila) 1(1):201-207, 2008. e-Pub 2008. PMID: 19138957.
- Yang Y, Iwanaga K, Raso MG, Wislez M, Hanna AE, Wieder ED, Molldrem JJ, Wistuba II, Powis G, Demayo FJ, Kim CF, Kurie JM. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One 3(5):e2220, 2008. e-Pub 2008. PMID: 18493606.
- Iwanaga K, Yang Y, Raso MG, Ma L, Hanna AE, Thilaganathan N, Moghaddam S, Evans CM, Li H, Cai WW, Sato M, Minna JD, Wu H, Creighton CJ, Demayo FJ, Wistuba II, Kurie JM. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res 68(4):1119-27, 2008. e-Pub 2008. PMID: 18281487.
- Raso MG, Wistuba II. Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers. J Thorac Oncol 2(7 Suppl 3):S128-35, 2007. e-Pub 2007. PMID: 17603309.
- Katayama H, Dou R, León-Letelier RA, Irajizad E, Sevillano A, Park S, Hsiao FC, Cai Y, Vykoukal J, Fahrmann J, Dennison J, Barrientos-Toro E, Raso MG, Sahin A, Hanash S. Aberrant expression of CD14 in breast tumor cells is associated with poor outcome.
Other Articles
- Barrientos-Toro, E, Ding, Q, Maria G Raso Translational Aspects in Metaplastic Breast Carcinoma. Cancers 16(7), 2024. PMID: 38611109.
- Batra, H, Mouabbi, JA, Ding, Q, Sahin, AA, Raso, M G Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights. Cancers 15(22), 2023. PMID: 38001750.
- Raso MG, Bota-Rabassedas N, Wistuba II Pathology and Classification of SCLC. Cancers (Basel) 13(4):1-11, 2021. PMID: 33669241.
- Tan, X, Banerjee, P, E, AP, Rutaganira, FU, Basu, K, Bota Rabassedas, MN, Guo, H, Grzeskowiak, CL, Liu, X, Yu, J, Shi, L, Peng, D, Rodriguez, B, Zhang, J, Zheng, V, Duose, D, Solis Soto, LM, Mino, B, Raso, G, Behrens, MC, Wistuba, II, Scott, KL, Smith, M, Nguyen, K, Lam, G, Choong, I, Mazumdar, A, Hill, J, Gibbons, DL, Brown, PH, Russell, W, Shokat, KM, Creighton, CJ, Glenn, JS, Kurie, JM Erratum. Science translational medicine 12(535), 2020. PMID: 32188723.
- Solis LM, Raso MG, Kalhor N, Behrens C, Wistuba II, Moran CA Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol 133(1):133-40, 2010. PMID: 20023269.
Abstracts
- Gao B, Huang C, Sullivan J, Raso G, Wistuba I, Shay J, Minna JD. Immortalization of Human Small Airway Epithelial Cells with Characteristics of Bronchioalveolar Stem Cells. IASLC 2009, 2009. e-Pub 2009.
- M Suraokar M, A Corvalan A, C Chow C, A Gazdar A, C Moran C, G Raso G, R Mehran R, A Tsao A, I Wistuba I. Integrating microRNA and mRNA expression profiling using a novel algorithm identified a small set of unique genes upregulated in malignant pleural mesothelioma (MPM), 2009. e-Pub 2009.
- Suroakar M, Corvalan A, Raso MG. Integrating microRNA and mRNA expression profiles identified a small set of unique genes upregulated in malignant pleural mesothelioma (MPM), 2009. e-Pub 2009.
- Cai D, Shames DS, Sullivan JP, Girard L, Peyton M, Gao B, Kim YH, Pollack J, Heymach J, Mills G, Raso G, Wistuba I, Kodadek TJ, Minna JD. Steroid receptor co-activator 3 (SRC-3, NCoA3): A new “addicting” oncogene and therapeutic target with EGFR TKIs for lung cancer, 2009. e-Pub 2009.
- LM Solis LM, MG Raso MG, C Behrens C, I Wistuba I, CA Moran CA. Primary Oncocytic Adenocarinoma of the Lung: Clinicopathological and Immunohistochemical Study of 16 cases, 2009. e-Pub 2009.
- LM Solis LM, MG Raso MG, C Behrens C, I Wistuba I, CA Moran CA. Primary Oncocytic Adenocarinoma of the Lung: Clinicopathological and Immunohistochemical Study of 16 cases, 2009. e-Pub 2009.
- Jin N, Cho SN, Jeong JW, Raso MG, Wistuba I, Evans CM, DeMayo FJ. Mig-6 is required for mouse lung development and tumor suppression, 2008. e-Pub 2008.
- ZhangJ, Iwanaga K, Choi K, Wislez M, Raso GM, Wei W, Wistuba I, Kurie J. 5-Epiregulin confers invasive properties to EGFR-dependent non-small cell lung cancer cells, 2008. e-Pub 2008.
- Raso MG, Behrens C, Li S, Woods D, Ozburn N, Moran C, Lee J, Wistuba I. Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of Non-small Cell Lung Cancers and Correlates with EGFR Mutations, 2008. e-Pub 2008.
- Yang Y, Iwanaga K, Raso G, Wislez M, Hanna A, Wieder E, Molldrem J, Wistuba I, Powis G, Demayo F, Kim C, Kurie J. Phosphatidylinositol 3-kinase stimulates the proliferation of bronchioalveolar stem cells in mouse models of oncogenic K-ras-induced lung cancer, 2008. e-Pub 2008.
- Raso MG, Behrens C, Li S, Prudkin L, Woods DM, Ozburn N, Moran C, Lee J, Wistuba I. Frequent expression of estrogen and progesterone receptors in the respiratory airway of non-small cell lung cancer patients suggests a field effect phenomenon, 2008. e-Pub 2008.
- Iwanaga K, Raso MG, Huaiguang L, Hanna AE, Wu H, Wistuba I, DeMayo FJ, Kurie JM. Rapid Onset of Lung Tumorigenesis in a Mouse Model Carrying Conditional Oncogenic Alleles for PTEN and K-ras, 2007. e-Pub 2007.
- Zhao M, DiPeri TP, Raso G, Rizvi YQ, Zheng X, Evans K, Akcakanat A, Yang F, Tripathy D, Dumbrava EI, Damodaran S, Meric-Bernstam F. Abstract 1791: Epigenetically upregulating TROP2 enhances therapeutic efficacy of TROP2 ADC sacitizumab govitecan. AACR 2022.
- Heeke :S, Gay CM, Estecio MR, Tran HT, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Arriola E, Hofman P, Kopparapu P, Lovly CM, Concannon K, Xi Y, Diao L, Wang Q, Wang J, Byers LA, Heymach AJ. Abstract 8577 Analysis of tumor- and circulating-free DNA methylation to identify clinically relevant small cell lung cancer subtypes. ASCO 2023.
- Raso MG. Abstract 5061 / 15 - Improved survival and unique mutational signatures in small cell lung cancer arising in patients with limited tobacco use. AACR 2024.
- Raso MG. Abstract Number: 864 Exploration of the circulating immune microenvironment stratified by breast cancer subtype. SITC 2024.
- Raso MG. Abstract Number: 1207 Artificial Intelligence-powered assessment of tumor microenvironment in pre-treatment and on-treatment biopsies informs treatment outcomes to pembrolizumab in patients with rare tumors. SITC 2024.
- Varadarajan K, Pico CX, Evans K, Raso MG, Rizvi Y, Zheng X, Diperi TP, Wang B, Scott S, Zhao M, Akcakanat A, Wengner AM, Yap TA, Meric-Bernstam F. Abstract 6180: Antitumor activity of the ATR inhibitor Elimusertib in patient-derived xenograft models with DNA damage response pathway alterations. AACR 2023.
- Raso MG, Xie Y, Behrens C, Woods D, Jeong Y, Mehran R, Mangelsdorf D, Moran C, Minna J, Wistuba I. Immunohistochemical Expression of Nuclear Receptors PPARg , LXR-b and LRH-1 in NSCLC. IASLC 2009.
- Batra H, Pandurengan RK, Ibarguen HP, McAllen SA, Ding Q, Sahin A, Wistuba I, Parra ER, Raso MG. Abstract P2-21-07: Exploring spatial correlations in Breast invasive Lobular Carcinoma subtypes using a novel CAF multiplex immunofluorescence panel. SABCS 2022.
- White BS, Woo XY, Koc S, Sheridan T, Neuhauser SB, Wang S, Evrard YA, Landua JD, R Jay Mashl R, Davies SR, Fang B, Raso MG, Evans KW, Bailey MH, Chen Y, Xiao M, Rubinstein J, pour AF, Dobrolecki LE, Fujita M, Fujimoto J, Xiao G, Fields RC, Mudd JL, Xu X, Hollingshead MG, Jiwani S, consortium P, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan C, Chen MS, Carvajal-Carmona LG, Welm AL, Welm BE, Govindan R, Li S, Davies MA, Roth JA, Meric-Bernstam F, Xie Y, Herlyn M, Ding L, Lewis MT, Bolt CJ, Dean DA, Chuang JH. Abstract 5407: A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis. AACR 2023.
- Yuca E, Evans K, Akcakanat A, Raso G, Rizvi YQ, Yang F, Byers L, Damodaran S, Daisuke O, Meric-Bernstam F. Abstract 1768: Anti-tumor activity and biomarker analysis for datopotamab deruxtecan in breast cancer PDX models. AACR 2022.
- Hernandez SD, Lu W, Serrano AG, Arrechedera CJ, Sanchez-Espiridion B, Ozirmak N, Molina M, Kostousov L, Barnes S, Khan K, Tang X, Fujimoto J, Parra ER, Raso G, Schmidt ST, Behrens C, Heymach J, Zhang J, Chen K, Sepesi B, Cascone T, Gibbons D, Wistuba II, Haymaker C, Solis LM. Abstract 4460: Spatial profiling of immune biomarkers in resected treatment-naïve early stage lung adenocarcinoma. AACR 2023.
- Mastoraki S, Lin J, Rao X, Liu SR, Batra H, Raso MG, Parra Cuentas ER, Raghavendra AS, Rasaputra KS, Yi M, Wang J, Sahin A, Tripathy D, Hunt KK, Navin NE, Keyomarsi K. Abstract 515: Single-cell transcriptomic analysis of HR+/HER2- breast cancer identifies gene signatures that predict outcomes of luminal A and B subtypes. AACR 2022.
- Zhou Y, Medik YB, Patel B, Zamler DB, Chen S, Chapman T, Schneider S, Babcock RL, Chrisikos TT, Kahn LM, Dyevoich AM, Park EM, Cogdill AP, Johnson DH, Johnson SB, Wani KM, Ledesma DA, Hudgens CW, Wang J, Wadud Khan MA, Joon AY, Peng W, Li HS, Arora R, Tang X, Raso MG, Zhang X, Foo WC, Tetzlaff MT, Diehl GE, Clise-Dwyer K, Whitley EM, Gubin MM, Allison JP, Hwu P, Ajami NJ, Diab A, Wargo JA, Watowich SS. Abstract 5545: Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. AACR 2022.
- DiPeri TP, Evans KW, Raso G, Rizvi YQ, Zheng X, Kirby B, Kong K, Keyomarsi K, Ajani JA, Yap TA, Meric-Bernstam F. Abstract 327: Antitumor efficacy of trastuzumab deruxtecan in combination with adavosertib in HER2-expressing Cyclin E amplified gastroesophageal cancers. AACR 2022.
- Heeke S, Gay CM, Estecio MR, Stewart A, Tran H, Zhang B, Tang X, Raso G, Concannon K, De Sousa LG, Lewis WE, Nilsson M, Xi Y, Diao L, Wang Q, Zhang J, Wang J, Wistuba II, Byers LA, Heymach JV. Abstract 3473: Use of DNA methylation from tumor and plasma to identify four major small cell lung cancer subtypes with distinct biology and therapeutic vulnerabilities. AACR 2022.
- White BS, Woo X, Koc S, Sheridan T, Neuhauser SB, Savaliya AM, Dobrolecki LE, Landua JD, Bailey MH, Fujita M, Evans KW, Fang B, Fujimoto J, Raso MG, Wang S, Xiao G, Xie Y, Davies SR, Fields RC, R Jay Mashl R, Mudd JL, Chen Y, Xiao M, Xu X, Hollingshead MG, Jiwani S, Consortium P, Evrard YA, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan C, Chen MS, Carvajal-Carmona LG, Welm AL, Welm BE, Lewis MT, Govindan R, Ding L, Li S, Herlyn M, Davies MA, Roth JA, Meric-Bernstam F, Bult CJ, Davis-Dusenbery B, Dean DA, Chuang JH. Abstract 1202: A repository of PDX histology images for exploring spatial heterogeneity and cancer dynamics. AACR 2022.
- Evans KW, Tzeng CD, Kwong L, Kahle MP, Zheng X, Li D, Tran Cao HS, Vu T, Kim S, Su F, Kirby B, Wathoo C, Raso G, Rizvi Y, Wang H, Janku F, Shaw K, Yap T, Javle M, Rodon J, Meric-Bernstam F. Abstract 2710: The MD Anderson patient-derived xenograft series for modeling precision oncology in biliary tract cancers. AACR 2021.
- Uzunparmak B, Haymaker C, Raso G, Zhu C, Masciari S, Wang L, Kirby B, Lin H, Gorur A, Cimo A, Kennon A, Ding Q, Palmieri A, Urschel GE, Yuan Y, Feng G, Rizvi Y, Hussain A, Subbiah V, Yap TA, Rodon-Ahnert J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Dumbrava EE. Abstract 961: HER2-low expression in patients with advanced or metastatic solid tumors. AACR 2023.
- Rahal Z, Hassane M, Karaoghlanian N, Zhang J, Sinjab A, J Jack Lee J, Raso MG, Fujimoto J, Chami H, Shihadeh A, Kadara H. Abstract 223: Chronic exposure to waterpipe smoke elicits immunomodulatory and carcinogenic effects in the lung. AACR 2022.
- Zhao M, Wang T, Gleber-Netto FO, Chen Z, McGrail DJ, Gomez JA, Ju W, Gadhikar MA, Ma W, Shen L, Tang X, Pathak S, Raso MG, Burks J, Lin S, Wang J, Multani AS, Pickering CR, Chen J, Myers JN, Zhou G. Abstract 2585: Mutant p53 gains oncogenic functions through a cytosolic DNA response. AACR 2023.
- Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan P, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran L, Krysan K, Behrens C, Duose D, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen DG, Heymach JV, Scheet P, Dubinett S, Wistuba II, Fujimoto J, Stevenson CS, Spira AE, Wang L. Abstract 130: Resolving the spatial and cellular architecture of lung adenocarcinoma by multi-region single-cell sequencing. AACR 2021.
- Concannon K, Heeke S, Sahu M, Tang X, Sasaki K, Patel S, Raso MG, Tran H, Gay C, Byers L. Abstract 1398: Clinical and transcriptomic analysis demonstrates improved survival and unique gene expression signatures among SCLC arising in patients with minimal tobacco use. AACR 2023.
- Ahmed J, Stephen B, Beyaz S, Chung C, Kilic E, Khawaja MR, Yang Y, Nick AM, Raso MG, Toro EB, Karp DD, Piha-Paul SA, Sood A, Ng C, Johnson AM, Soliman PT, Meric-Bernstam F, Lu KH, Naing A. Abstract A121: Temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. AACR-NCI-EORTC 2024 International Conference on Molecular Targets and Cancer Therapeutics.
- Raso MG. Abstract 109 PD-L1 Expression by Immunohistochemistry: Comparison Between Tissue Microarrays and Whole Slide Sections in Breast Carcinoma. USCAP 2023.
Selected Presentations & Talks
Local Presentations
- 2025. CCSG Tissue Biospecimen and Pathology Resources. Invited. MDACC Research Town Hall. Houston, Texas, US.
- 2025. Enhancing Pathology Knowledge for Biomedical Scientists: A Comprehensive Self-Paced Online Curriculum for Bridging Fundamental Concepts and Translational Applications. Invited. MDACC Educational Week. Houston, TX, US.
- 2024. Tissue Biospecimen and Pathology Resource (TBPR). Invited. CCSG EAB Review. Houston, Texas, US.
- 2023. RNAscope Co-Detection Service Launch Event. Invited. MDACC RHCL RNAscope Co-Detection Lunch and Learn Service Launch Event, US.
- 2018. Interdisciplinary Research Methods in the Research Histology Core Laboratory Facility (RHF). Invited. TMP 2018 Retreat. Houston, Texas, US.
National Presentations
- 2025. The AI Evolution: Transforming Clinical, Translational, and Research Pathology. Invited. 2025 IEEE International Symposium on Biomedical Imaging (ISBI). Houston, TX, US.
- 2023. A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis. Conference. AACR 2021, US.
- 2023. PD-L1 Expression by Immunohistochemistry: Comparison Between Tissue Microarrays and Whole Slide Sections in Breast Carcinoma. USCAP 2023, US.
- 2022. Exploring spatial correlations in Breast invasive Lobular Carcinoma subtypes using a novel CAF multiplex immufluorescence. Conference. SACBS 2022, US.
- 2021. The MD Anderson patient-derived xenograft series for modeling precision oncology in biliary tract cancers. Conference. AACR 2022, US.
- 2009. Nuclear Receptors in Lung cancer. Conference. IASLC 2009. San Francisco, CA, US.
- 2009. Lung Cancer Tissue Bank at MD Anderson Cancer Center: Role of a Specialized Tissue Bank in a Multidisciplinary Research Program. Conference. ISBER 2009. Portland, OR, US.
- . Conference. AACR 2008. San Diego, CA, US.
- 2008. Mig-6 is required for mouse lung development and tumor suppression. Conference. AACR 2008. San Diego, CA, US.
- 2008. Epiregulin confers invasive properties to EGFR-dependent non-small cell lung cancer cells. Conference. AACR 2008. San Diego, CA, US.
- 2008. Phosphatidylinositol 3-kinase stimulates the proliferation of bronchioalveolar stem cells in mouse models of oncogenic K-ras-induced lung cancer. Conference. AACR 2008. San Diego, CA, US.
- 2008. Frequent expression of estrogen and progesterone receptors in the respiratory airway of non-small cell lung cancer patients suggests a field effect phenomenon. Conference. IASLC 2008. Santa Monica, CA, US.
- 2007. Rapid Onset of Lung Tumorigenesis in a Mouse Model Carrying Conditional Oncogenic Alleles for PTEN and K-ras. Conference. AACR 2007. Los Angeles, CA, US.
International Presentations
- 2025. “The AI Evolution: Transforming Clinical, Translational, and Research Pathology”. Invited. International Symposium on Biomedical Imaging (ISBI). Houston, US.
- 2008. Biobanks in USA. Conference. IV Latin American Biobanks Conference. Buenos Aires, AR.
Grant & Contract Support
| Date: | 2023 - 2030 |
| Title: | SPONSORED CLINICAL STUDY AGREEMENT |
| Funding Source: | Private Industry |
| Role: | Co-I |
| ID: | 0015684 |
| Date: | 2022 - 2025 |
| Title: | LCMC4 |
| Funding Source: | research agreement Genentech/LCRF Agrmnt. - LCMC4 |
| Role: | Co-I |
| ID: | 149100-30-123859-46 |
| Date: | 2021 - 2024 |
| Title: | Targeting ROR1 Overexpressing Cancer |
| Funding Source: | BOEHRINGER INGELHEIM PHARM INC (Private Industry) |
| Role: | Key |
| ID: | 00012980 |
| Date: | 2021 - 2026 |
| Title: | RCTS 59261 |
| Funding Source: | NIH |
| Role: | Consult |
| ID: | 00012313 |
| Date: | 2020 - 2027 |
| Title: | 2019-1175 A Phase 1/2, Open |
| Funding Source: | Research Agreement Black Diamond Therapeutics (Private Industry) |
| Role: | Co-I |
| ID: | 00011940 |
| Date: | 2020 - 2025 |
| Title: | Core B Pathology |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | 00011836 |
| Date: | 2020 - 2026 |
| Title: | Texas Experimental Cancer Therapeutics Network – TEX-CTN |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 5UM1CA186688 |
| Date: | 2020 - 2023 |
| Title: | Investigating the role of CD38 as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP200235 |
| Date: | 2019 - 2026 |
| Title: | Cancer Center Support Grant (CCSG) |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| ID: | 5P30CA016672-41 |
| Date: | 2018 - 2024 |
| Title: | Core 2: Rational Combination Treatment Options to Reverse Resistance in Hormone Receptor Positive Breast Cancer Refractory to Standard Therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP180712 |
| Date: | 2016 - 2024 |
| Title: | SIV EMD Serono Strategic Collaboration Agreement |
| Funding Source: | EMD SERONO INC |
| Role: | Co-I |
| ID: | CS2017-00053902-LG |
| Date: | 2016 - 2021 |
| Title: | Defining and Defeating Mechanistic Subtypes of KRAS-Mutant Lung Cancers |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Core Leader |
| ID: | RP160652 |
Patient Reviews
CV information above last modified May 06, 2025